ABSTRACT We address the problem of expected cost minimization of meeting the uncertain fuel demand during a time planning horizon, where supply is provided by selecting discrete shipments with lead times. Due to uncertainty and the passage of time, corrective actions can be taken such as cancellation and postponement on supply of shipments with associated costs and delays. This problem is modeled as a stochastic multi-stage capacitated discrete lot-sizing problem with lead times. Computational experiments were performed on the resolution of various instances of the model for four information structures of uncertainty. The experimental optimal values and stochastic rating measures obtained show the validity and interest of the stochastic model, as well as the benefits that can be obtained with respect to a deterministic variant of the model that considers average demand.

Alstroemeria pulchra var. maxima is an endemic Chilean taxon described by R.A. Philippi in 1864, whose taxonomic position is controversial; even though Bayer in 1987 transferred this taxon to A. magnifica with the rank of subspecies, Muñoz & Moreira in 2003 return to the original concept proposed by Philippi. In order to provide a new character to decide if A. pulchra var. maxima is a member of the A. magnifica complex or must remain as a variety of A. pulchra as was originally described, the color of outer, upper inner and lower inner tepals of the flowers of eight populations of Alstroemeria L. belonging to these two endemic Chilean species were analyzed with a spectrophotometer colorimeter Hunterlab Colorquest: five populations of A. magnifica Herbert and three populations of A. pulchra Sims. CIELab coordinates allow to separate A. magnifica from A. pulchra on the basis of the color of the outer and lower inner tepals but not by the color of the upper inner tepals. We conclude that the color of the flower is a new character to confirm that var. maxima belong to A. pulchra, not to the A. magnifica complex.

Alstroemeria pulchra var. maxima es un taxón endémico de Chile descrito por R.A. Philippi en 1864, cuya posición sistemática es controversial; aunque Bayer en 1987 transfiere este taxón a A. magnifica con el rango de subespecie, Muñoz & Moreira en 2003 retoman el concepto original de Philippi. Con el objetivo de proporcionar nuevos caracteres para decidir si A. pulchra var. maxima es un miembro del complejo A. magnifica o debe permanecer como una variedad de A. pulchra como fue originalmente descrita, se analizó el color de los tépalos externos, internos superiores e interno inferior, utilizando un espectrofotómetro colorímetro Hunterlab Colorquest. Se trabajó con flores de ocho poblaciones de Alstroemeria L. pertenecientes a estas dos especies endémicas de Chile: cinco poblaciones de A. magnifica Herbert y tres poblaciones de A. pulchra Sims. Las mediciones en el espacio CIELab permiten distinguir A. magnifica de A. pulchra sobre la base del color de los tépalos externos y del tépalo interno inferior, pero no por el color de los tépalos internos superiores. Se concluye que el color de la flor es un nuevo carácter que confirma que la var. maxima pertenece a A. pulchra y no al complejo A. magnifica.

Background: Guidelines for the management of unstable angina (UA) and non ST elevation myocardial infarction (NSTEMI) have been issued, however cu-rrent practices are unknown in Chile. Aitn: To evalúate in a prospective cohort of NSTEMI patients the current practices, treatments and risk factors. Material and Methods: Oneyear prospective International non interventional registry, conducted in Chile between January 2005 and November 2006. Results: Two hundred thirty three Chilean NSTEMI patients were enrolled. Mortality was 5.5% at the end ofthe follow-up. Mean age was 61.6 years, and 30.6% were female. Most of the patients had at least one risk factor (98%): hypertension (84%), previous myocardial infarction (33%), dyslipidemia (54%), diabetes (33%), current smoking (30%). Main procedures duringthe hospitalization were coronary angiogram (67%), angioplasty (33%; 88% with stent) and coronary bypass surgery (7%). Duringprocedures, 31% of patients received clopidogrel, and 4.2% glycoprotein Ilb/IIIa antagonists. Medical management was selected for 60% of patients. In comparison to men, women received less interventional procedures despite havingmore risk factors. Treatments prescribed at discharge were aspirin (97%), clopidogrel (49%), beta blockers (78%), diuretics (21%), lipid lowering agents (78%), oral hypoglycemic agents (13%) and insulin (9%). At the end ofthe 1-year follow-up, treatments were aspirin (84%), beta blockers (72%), diuretics (19%), and dual antiplatelet therapy with clopidogrel (16%). Conclusions: A high prevalence of múltiple risk factors for cardiovascular disease in Chilean patients with NSTEMI was observed. More aggressive primary and secondary preventive measures are urgently needed. Use of therapies proposed in the guidelines is high, but dual antiplatelet therapy is less than 50% at discharge and decreases during the one year-follow-up.